Literature DB >> 6289730

Treatment of experimental Salmonella typhimurium infection with mecillinam and ampicillin.

T Butler, C W Shuster, P Dixon.   

Abstract

The activities of mecillinam and ampicillin, alone and in combination, were evaluated in mice infected with the LT-2 strain of Salmonella typhimurium. The minimal inhibitory concentrations of mecillinam and ampicillin for this strain were, respectively, 6.2 and 0.4 microgram/ml of culture medium. In vitro synergy was demonstrated. CF-1 mice inoculated intraperitoneally with 10(4) colony-forming units of the LT-2 strain were used in the therapeutic assessments. Treatment of subgroups with graded doses of the respective penicillins or their combination was initiated 24 h after inoculation and repeated at 6-h intervals for 5 consecutive days. Animals were observed during 21 days for mortality or sacrificed for quantitative cultures of spleen homogenates at the end of the treatment. Ampicillin in doses of greater than or equal to 0.03 mg and mecillinam in doses of greater than or equal to mg reduced mortality rates from 77% in the saline-treated controls to a range of 0 to 4% (P less than 0.05). The same doses of antibiotics also extended the median times to death and lowered significantly the means of splenic bacterial counts. When both drugs were combined in doses that were partially effective or subinhibitory alone, no synergistic effects were observed. These results showed that mecillinam and ampicillin given alone were effective in treating S. typhimurium infection but that combinations of the two drugs were not synergistic in controlling the course of infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6289730      PMCID: PMC181421          DOI: 10.1128/AAC.19.2.328

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

2.  High and selective resistance to mecillinam in adenylate cyclase-deficient or cyclic adenosine 3',5'-monophosphate receptor protein-deficient mutants of Escherichia coli.

Authors:  R Aono; M Yamasaki; G Tamura
Journal:  J Bacteriol       Date:  1979-02       Impact factor: 3.490

3.  Mecillinam in enteric fever.

Authors:  B K Mandal; A G Ironside; J Brennand
Journal:  Br Med J       Date:  1979-03-03

4.  The mechanism of action of mecillinam.

Authors:  B G Spratt
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

5.  Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12.

Authors:  B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

6.  In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics.

Authors:  E Grunberg; R Cleeland; G Beskid; W F DeLorenzo
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

7.  Mecillinam-ampicillin synergism in experimental Enterobacteriaceae meningitis.

Authors:  W M Scheld; F N Fink; D D Fletcher; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

8.  Therapy of antimicrobial-resistant typhoid fever.

Authors:  T Butler; N N Linh; K Arnold; M D Adickman; D M Chau; M M Muoi
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

9.  Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.

Authors:  J C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

10.  Effect of a Salmonella group H1 R factor on virulence and response of infections to antimicrobial therapy.

Authors:  T Butler; C W Shuster; A Franco
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more
  3 in total

1.  Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice.

Authors:  H Brunner; H J Zeiler
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles.

Authors:  E Fattal; M Youssef; P Couvreur; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection.

Authors:  P A Anton; J A Kemp; T Butler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.